Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Robert F Storey

Showing results (281-290 of 401) with videos related to

Pageof 41
Sort By:
American Heart Journal|June 15, 2016
Impact of glycoprotein IIb/IIIa inhibitors on the efficacy and safety of ticagrelor compared with clopidogrel in patients with acute coronary syndromes: Analysis from the Platelet Inhibition and Patient Outcomes (PLATO) TrialYuichi J Shimada, Sameer Bansilal, Stephen D Wiviott, et al.
European Heart Journal. Acute Cardiovascular Care|February 23, 2021
Biomarkers of coagulation and fibrinolysis in acute myocardial infarction: a joint position paper of the Association for Acute CardioVascular Care and the European Society of Cardiology Working Group on ThrombosisKonstantin A Krychtiuk, Walter S Speidl, Evangelos Giannitsis, et al.
JACC. Cardiovascular Imaging|November 10, 2022
Plaque Burden and 1-Year Outcomes in Acute Chest Pain: Results From the Multicenter RAPID-CTCA TrialMohammed N Meah, Evangelos Tzolos, Kang-Ling Wang, et al.
European Heart Journal|December 8, 2022
Acute, periprocedural and longterm antithrombotic therapy in older adults: 2022 Update by the ESC Working Group on ThrombosisFelicita Andreotti, Tobias Geisler, Jean-Philippe Collet, et al.
Circulation|November 20, 2009
Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET studyPaul A Gurbel, Kevin P Bliden, Kathleen Butler, et al.
Thrombosis and Haemostasis|March 17, 2017
Consistent platelet inhibition with ticagrelor 60 mg twice-daily following myocardial infarction regardless of diabetes statusMark R Thomas, Dominick J Angiolillo, Marc P Bonaca, et al.
European Heart Journal|May 4, 2015
Effect of genetic variations on ticagrelor plasma levels and clinical outcomesChristoph Varenhorst, Niclas Eriksson, Åsa Johansson, et al.
Circulation|May 11, 2012
Ticagrelor versus clopidogrel in patients with acute coronary syndromes and a history of stroke or transient ischemic attackStefan K James, Robert F Storey, Nardev S Khurmi, et al.
Circulation|March 3, 2010
Response to ticagrelor in clopidogrel nonresponders and responders and effect of switching therapies: the RESPOND studyPaul A Gurbel, Kevin P Bliden, Kathleen Butler, et al.
American Heart Journal|April 30, 2017
Balancing the risk of spontaneous ischemic and major bleeding events in acute coronary syndromesGregory Ducrocq, Phillip J Schulte, Andrzej Budaj, et al.
Pageof 41

Showing results (281-290 of 401) with videos related to

Sort By:
Pageof 41
American Heart Journal|June 15, 2016
Impact of glycoprotein IIb/IIIa inhibitors on the efficacy and safety of ticagrelor compared with clopidogrel in patients with acute coronary syndromes: Analysis from the Platelet Inhibition and Patient Outcomes (PLATO) TrialYuichi J Shimada, Sameer Bansilal, Stephen D Wiviott, et al.
European Heart Journal. Acute Cardiovascular Care|February 23, 2021
Biomarkers of coagulation and fibrinolysis in acute myocardial infarction: a joint position paper of the Association for Acute CardioVascular Care and the European Society of Cardiology Working Group on ThrombosisKonstantin A Krychtiuk, Walter S Speidl, Evangelos Giannitsis, et al.
JACC. Cardiovascular Imaging|November 10, 2022
Plaque Burden and 1-Year Outcomes in Acute Chest Pain: Results From the Multicenter RAPID-CTCA TrialMohammed N Meah, Evangelos Tzolos, Kang-Ling Wang, et al.
European Heart Journal|December 8, 2022
Acute, periprocedural and longterm antithrombotic therapy in older adults: 2022 Update by the ESC Working Group on ThrombosisFelicita Andreotti, Tobias Geisler, Jean-Philippe Collet, et al.
Circulation|November 20, 2009
Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET studyPaul A Gurbel, Kevin P Bliden, Kathleen Butler, et al.
Thrombosis and Haemostasis|March 17, 2017
Consistent platelet inhibition with ticagrelor 60 mg twice-daily following myocardial infarction regardless of diabetes statusMark R Thomas, Dominick J Angiolillo, Marc P Bonaca, et al.
European Heart Journal|May 4, 2015
Effect of genetic variations on ticagrelor plasma levels and clinical outcomesChristoph Varenhorst, Niclas Eriksson, Åsa Johansson, et al.
Circulation|May 11, 2012
Ticagrelor versus clopidogrel in patients with acute coronary syndromes and a history of stroke or transient ischemic attackStefan K James, Robert F Storey, Nardev S Khurmi, et al.
Circulation|March 3, 2010
Response to ticagrelor in clopidogrel nonresponders and responders and effect of switching therapies: the RESPOND studyPaul A Gurbel, Kevin P Bliden, Kathleen Butler, et al.
American Heart Journal|April 30, 2017
Balancing the risk of spontaneous ischemic and major bleeding events in acute coronary syndromesGregory Ducrocq, Phillip J Schulte, Andrzej Budaj, et al.
Pageof 41